LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
A blueprint for changing diabetes in Indonesia
Among the 242 million people living in Indonesia, 7.6 million have diabetes but less than 1% is achieving recommended treatment targets. In its fifth Blueprint for Change business case published, Novo Nordisk examines four barriers that prevent quality and accessibility of diabetes care and identifies the opportunities to address them.

“If action is not taken, demand for healthcare will outstrip Indonesia’s ability to provide it,” says Charlotte Ersbøll, corporate vice president, Global Stakeholder Engagement, Novo Nordisk. “In the end, it will be people with diabetes and their families that will carry the highest cost.”

The Indonesia Blueprint for Change recommends investments in diabetes awareness, increasing the supply of healthcare professionals specializing in diabetes care and improving diabetes education among internists and general practitioners. Concrete action suggested is the need to involve more levels of healthcare professionals, including nurses and diabetes educators. A final conclusion from the case is the need to make these investments in partnerships.

“Novo Nordisk is committed to working together with local authorities, investors and NGOs to build trust and confidence among patients, healthcare practitioners and policy makers,” says Sandeep Sur, general manager, Novo Nordisk Indonesia. “We must leverage all our joint capabilities and competences if we want to improve knowledge, treatment and better care.”

According to the analysis, improved awareness, accessibility, affordability and quality of care could reduce both diabetes-related complications and costs. Over the remaining lifetime of people with diabetes in Indonesia, more than 37,000 diabetes-related heart attacks and more than 400,000 diabetes-related kidney failures could be prevented, nearly 6 billion USD could be saved in diabetes treatment costs and more than 4.6 million life-years could be gained.

Click here for the complete issue.


Credits to: American Chemical Society

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy